• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Medicus Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    11/14/25 5:17:30 PM ET
    $MDCX
    Get the next $MDCX alert in real time by email
    Medicus Pharma Ltd.: Form 8-K - Filed by newsfilecorp.com

    false 2025-11-14 0001997296 Medicus Pharma Ltd. 0001997296 2025-11-14 2025-11-14 0001997296 exch:XNCM mdcx:CommonSharesNoParValueMember 2025-11-14 2025-11-14 0001997296 exch:XNCM mdcx:WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember 2025-11-14 2025-11-14

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 14, 2025

    MEDICUS PHARMA LTD.
    (Exact name of registrant as specified in its charter)

    Ontario 001-42408 98-1778211
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    300 Conshohocken State Road, Suite 200
    Conshohocken, Pennsylvania, United States 19428
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (610) 540-7515

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common shares, no par value   MDCX   NASDAQ Capital Market
    Warrants, each exercisable for one common share at an exercise price of $4.64 per share   MDCXW   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    Item 8.01. Other Events.

    On November 14, 2025, the Company issued a press release relating to its financial and operating results for the quarter ending September 30, 2025, and other corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit
    No.
      Description
    99.1   Press Release, dated November 14, 2025.
    104   Cover Page Interactive Data File (formatted as Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

    MEDICUS PHARMA LTD.
       
    By: /s/ Raza Bokhari
    Name: Dr. Raza Bokhari
    Title: Executive Chairman and Chief Executive Officer

    Dated: November 14, 2025


    Get the next $MDCX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDCX
    SEC Filings

    View All

    SEC Form S-1 filed by Medicus Pharma Ltd.

    S-1 - Medicus Pharma Ltd. (0001997296) (Filer)

    11/19/25 5:00:34 PM ET
    $MDCX

    SEC Form EFFECT filed by Medicus Pharma Ltd.

    EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

    11/17/25 12:15:23 AM ET
    $MDCX

    SEC Form EFFECT filed by Medicus Pharma Ltd.

    EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

    11/17/25 12:15:24 AM ET
    $MDCX

    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mahaffy Patrick J claimed ownership of 35,435 shares (SEC Form 3)

    3 - Medicus Pharma Ltd. (0001997296) (Issuer)

    9/8/25 4:36:44 PM ET
    $MDCX

    Amendment: New insider Smith Andrew Alasdair claimed ownership of 164 shares (SEC Form 3)

    3/A - Medicus Pharma Ltd. (0001997296) (Issuer)

    8/6/25 4:36:34 PM ET
    $MDCX

    SEC Form 3 filed by new insider Rodgers Cathy Mcmorris

    3 - Medicus Pharma Ltd. (0001997296) (Issuer)

    7/31/25 10:36:14 AM ET
    $MDCX

    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    PHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has submitted an FDA Commissioner's national priority voucher (CNPV) application on behalf of Skinject (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The submission includes a complete Statement of Interest outlining SkinJect's alignment with FDA national priorities in cancer care access, affordability, and rare-disease needs.  

    11/17/25 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

    PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Adm

    10/29/25 7:30:00 AM ET
    $MDCX

    Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance

    Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, announces significant changes within the Board of Directors. As mentioned in the press release dated July 29, 2025 following the agreement signed by Poxel and its directors with the senior creditor of the Company, and in the context of the filing for the insolvency ("déclaration de cessation des paiements") and request for opening of reorganization proceedings ("redressement judiciaire") with the C

    8/1/25 1:30:00 AM ET
    $MDCX

    $MDCX
    Financials

    Live finance-specific insights

    View All

    Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

    PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Adm

    10/29/25 7:30:00 AM ET
    $MDCX

    $MDCX
    Leadership Updates

    Live Leadership Updates

    View All

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care